42,72 €
2,28 % heute
L&S, 9. Juli, 15:10 Uhr
ISIN
US4330001060
Symbol
HIMS
Berichte

Hims & Hers Health Inc. Aktie News

Positiv
CNBC
12 Minuten alt
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Neutral
Business Wire
12 Minuten alt
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering...
Neutral
PRNewsWire
etwa 18 Stunden alt
NEW YORK , July 8, 2025 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against: Hims & Hers Health, Inc. (NYSE: HIMS) Shareholders should email Fletcher@fmoorelaw.com The investigation concerns a recent announcement about the Novo Nordisk collaboration. On April 29, 2025, Hims & Hers announced a long-term collaboratio...
Neutral
PRNewsWire
etwa 23 Stunden alt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson  Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Hims  between April 29, 2025 and June 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-...
Positiv
Seeking Alpha
etwa 23 Stunden alt
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting retention and average revenue per user to $84. Despite the Novo Nordisk split, the diversified GLP-1 and weight loss portfolio targets $725 million in 2025 specialty revenue.
Neutral
GlobeNewsWire
2 Tage alt
LOS ANGELES, July 07, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 25, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”).
Neutral
PRNewsWire
2 Tage alt
NEW YORK , July 7, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the "Class Period"), of the important August 25, 2025 lead plaintiff deadline. So what: If you purchased Hims common stock during the Class Period you may be ent...
Neutral
GlobeNewsWire
3 Tage alt
RADNOR, Pa., July 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS) on behalf of those who purchased or otherwise acquired Hims & Hers securit...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen